Scancell Ltd.
- Country
- ๐ฌ๐งUnited Kingdom
- Ownership
- Public, Subsidiary
- Established
- 1996-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)โข Click on a phase to view related trials
Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer
- Conditions
- Triple Negative Breast CancerRenal Cell CancerSquamous Cell Carcinoma of the Head and NeckHigh Grade Ovarian Serous Adenocarcinoma
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- Scancell Ltd
- Target Recruit Count
- 144
- Registration Number
- NCT05329532
- Locations
- ๐ฌ๐ง
Brighton and Sussex University Hospital, Brighton, Default, United Kingdom
๐ฌ๐งUniversity Hospitals Bristol and Weston NHS Foundation Trust, Bristol, Default, United Kingdom
๐ฌ๐งVelindre Cancer Centre, Cardiff, Default, United Kingdom
A First Time in Human Phase 1 Open-Label Study of the COVIDITY Vaccine Administered by Needle-free Injection
- Conditions
- COVID-19
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2022-11-25
- Lead Sponsor
- Scancell Ltd
- Target Recruit Count
- 80
- Registration Number
- NCT05047445
- Locations
- ๐ฟ๐ฆ
University of Cape Town Lung Institute, Centre for TB Research Innovation, Cape Town, Western Cape, South Africa
SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
- Conditions
- Malignant MelanomaMelanoma (Skin)Melanoma Stage IVMelanoma Stage III
- Interventions
- Biological: SCIB1 or iSCIB1+ DNA vaccine
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Scancell Ltd
- Target Recruit Count
- 173
- Registration Number
- NCT04079166
- Locations
- ๐ฌ๐ง
Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
๐ฌ๐งVelindre University NHS Trust, Cardiff, United Kingdom
๐ฌ๐งThe Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Study of a DNA Immunotherapy to Treat Melanoma
- Conditions
- Malignant Melanoma
- First Posted Date
- 2010-06-07
- Last Posted Date
- 2017-08-21
- Lead Sponsor
- Scancell Ltd
- Target Recruit Count
- 35
- Registration Number
- NCT01138410
- Locations
- ๐ฌ๐ง
Department of Medical Oncology, The Royal Surrey County Hospital, Guildford, Surrey, United Kingdom
๐ฌ๐งSt James' Institute of Oncology, Leeds, United Kingdom
๐ฌ๐งChristie Hospital, Manchester, United Kingdom